(0.30%) 5 115.51 points
(0.30%) 38 356 points
(0.36%) 15 985 points
(-0.97%) $83.04
(5.36%) $2.03
(0.30%) $2 354.20
(0.56%) $27.69
(4.31%) $961.80
(-0.27%) $0.932
(-0.45%) $10.98
(-0.59%) $0.796
(1.63%) $93.37
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 10.01%
@ $46.45
発行日: 30 4月 2024 @ 01:25
リターン: 0.80%
前回のシグナル: 4月 29 - 22:30
前回のシグナル:
リターン: 1.07 %
Live Chart Being Loaded With Signals
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer...
Stats | |
---|---|
本日の出来高 | 260 464 |
平均出来高 | 1.14M |
時価総額 | 3.45B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-1.190 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.09 |
ATR14 | $1.730 (3.70%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ashar Bhavesh | Sell | 1 824 | Common Stock |
2024-02-16 | Pichl Daniel | Buy | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Stock Option (Right to Buy) |
2024-02-02 | Ashar Bhavesh | Sell | 1 089 | Common Stock |
INSIDER POWER |
---|
25.98 |
Last 99 transactions |
Buy: 2 487 277 | Sell: 1 935 911 |
ボリューム 相関
Springworks Therapeutics 相関
10 最も負の相関 | |
---|---|
TUEM | -0.915 |
NAKD | -0.9 |
CYTO | -0.897 |
PROC | -0.895 |
AHPI | -0.894 |
PCSA | -0.89 |
LCAP | -0.883 |
MTEX | -0.874 |
TRIT | -0.874 |
VIEW | -0.872 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Springworks Therapeutics 相関 - 通貨/商品
Springworks Therapeutics 財務諸表
Annual | 2023 |
収益: | $5.45M |
総利益: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2023 |
収益: | $5.45M |
総利益: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2022 |
収益: | $6.15M |
総利益: | $4.25M (69.16 %) |
EPS: | $-5.14 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-4.02 |
Financial Reports:
No articles found.
Springworks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。